- |||||||||| Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca, budesonide/formoterol (PT009) / AstraZeneca
Trial completion date, Trial primary completion date: Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS) (clinicaltrials.gov) - Jan 13, 2022 P3, N=2200, Recruiting, Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Jul 2023 --> Jan 2024 | Trial primary completion date: Jul 2023 --> Jan 2024
- |||||||||| Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca, budesonide/formoterol (PT009) / AstraZeneca
Trial completion date, Trial primary completion date: Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS) (clinicaltrials.gov) - Jan 13, 2022 P3, N=2200, Recruiting, Trial completion date: Jul 2023 --> Jan 2024 | Trial primary completion date: Jul 2023 --> Jan 2024 Trial completion date: Sep 2023 --> Mar 2024 | Trial primary completion date: Sep 2023 --> Mar 2024
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Blincyto (blinatumomab) / Astellas, Amgen, Rituxan (rituximab) / Roche
Trial initiation date, Combination therapy: NCI-2021-01791: Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia (clinicaltrials.gov) - Jan 13, 2022 P1, N=20, Not yet recruiting, Trial completion date: Sep 2023 --> Mar 2024 | Trial primary completion date: Sep 2023 --> Mar 2024 Initiation date: Aug 2021 --> Feb 2022
- |||||||||| Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma
New P2 trial: Loncastuximab Tesirine in WM (clinicaltrials.gov) - Jan 12, 2022 P2, N=36, Not yet recruiting,
- |||||||||| dexamethasone injection / Generic mfg.
Journal: Effects of dexamethasone on foetal Doppler flow velocimetry. (Pubmed Central) - Jan 12, 2022 With the improvement of foetal respiratory outcome in both groups.What are the implications of these finding for clinical practice and/or further research? Maternal Dexamethasone injection is recommended for mothers at risk of preterm labour, especially if delivery is expected within six days and mothers who will undergo elective CS before completion of 39 weeks of gestation, in terms of improving neonatal respiratory functions and decreasing the possibility of admission to neonatal intensive care unit for transient tachypnoea of the newborn.
- |||||||||| GSK870086 inhalation / GSK, mapracorat (BOL-303242-X) / Bayer, fosdagrocorat (PF-04171327) / Pfizer
Review, Journal: Dimerization of glucocorticoid receptors and its role in inflammation and immune responses. (Pubmed Central) - Jan 12, 2022 Furthermore, some studies have shown that some selective glucocorticoid receptor agonists and modulators (SEGRAMs) have good separation characteristics (i.e., preferentially mediate the transrepression of proinflammatory genes or preferentially activate anti-inflammatory target genes). This article reviewed the formation of GR dimers, the role of GR dimers in the inflammation and immune responses, and the progress of SEGRAMs to provide novel ideas for further understanding the anti-inflammatory mechanism of GR and the development of SEGRAMs.
- |||||||||| Sarclisa (isatuximab-irfc) / Sanofi
Clinical, P3 data, Journal: Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. (Pubmed Central) - Jan 12, 2022 P3 This article reviewed the formation of GR dimers, the role of GR dimers in the inflammation and immune responses, and the progress of SEGRAMs to provide novel ideas for further understanding the anti-inflammatory mechanism of GR and the development of SEGRAMs. The addition of isatuximab to carfilzomib-dexamethasone significantly improves progression-free survival and depth of response in patients with relapsed multiple myeloma, representing a new standard of care for this patient population.
- |||||||||| dexamethasone / Generic mfg.
Journal: Effect of Three NR3C1 mutations in Pathogenesis of Pituitary ACTH Adenoma. (Pubmed Central) - Jan 12, 2022 Our findings identify 3/49 (6.1%) consecutive human corticotroph tumors harboring GR mutations. Further findings demonstrate the role NR3C1 plays in CD pathogenesis and offer insights into a novel treatment approach in this patient subset.
- |||||||||| Xpovio (selinexor) / Karyopharm
Enrollment open: Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 12, 2022 P2, N=25, Recruiting, Our data, which show that treatment decreases neonatal morbidity and overall mortality without increasing overall pregnancy complications, warrant further study. Not yet recruiting --> Recruiting
- |||||||||| dexamethasone / Generic mfg.
Preclinical, Journal: New calcification model for intact murine aortic valves. (Pubmed Central) - Jan 11, 2022 Aortic valves of wild-type mice were cultured in the MTCS and exposed to osteogenic medium (OSM, containing ascorbic acid, β-glycerophosphate and dexamethasone) or inorganic phosphates (PI)...In conclusion, we have established an ex vivo calcification model for intact wild-type murine aortic valves in which the initiation and progression of aortic valve calcification can be studied. The in vitro-ex vivo differences found in our studies underline the importance of ex vivo models to facilitate pre-clinical translational studies.
- |||||||||| dexamethasone / Generic mfg.
Journal: DHEAS and Differential Blood Counts as Indirect Signs of Glucocorticoid Excess in Adrenal Non-Producing Adenomas. (Pubmed Central) - Jan 11, 2022 Since glucocorticoids are potent immunosuppressants we studied blood counts and differential blood counts along with corticotropin and dehydroepiandrostenedione sulfate (DHEAS) blood concentrations, as well as cortisol values before and after an overnight 1 mg dexamethasone suppression test...We also found that the extent of lymphocytopenia correlated with the concentrations of DHEAS and ACTH, and DHEAS correlated well with ACTH. We conclude that the basal ACTH and DHEAS values along with the differential blood counts give good information on the extent of glucocorticoid excess and that silent adrenal adenomas seem to oversecrete glucocorticoids at concentrations that already alter these parameters.
- |||||||||| dexamethasone / Generic mfg.
Journal: Optimized Clustering Algorithm for Comparative Analysis of Different Prenatal Corticosteroid Neurological Deficits in Premature Infants through Magnetic Reasoning Imaging (MRI). (Pubmed Central) - Jan 11, 2022 100 pregnant women with threatened preterm labor were retrospectively analyzed, in which 38 pregnant women with lasting threatened preterm labor (group A) were treated with multiple courses of antenatal corticosteroids (dexamethasone treatment) and 62 cases of pregnant women with threatened preterm labor (group B) were treated with single course of dexamethasone treatment...MRI images based on optimized clustering algorithm can be used in the diagnosis of neonatal hypoxic-ischemic encephalopathy. There is no significant difference in the application of different antenatal corticosteroids affecting premature nerve function defect and prognosis, but multiple courses of antenatal corticosteroids can affect neonatal body mass and increased maternal complications to a certain extent; therefore, before threatened premature delivery treatment, the pros and cons of multiple courses of antenatal corticosteroids should fully be considered and in the treatment, measures should be actively taken to alleviate the side effect.
- |||||||||| dexamethasone / Generic mfg., amikacin sulfate / Generic mfg.
Journal: Determination of amikacin stability at 1% and 3% concentrations in four topical solutions over a 56 day period. (Pubmed Central) - Jan 11, 2022 Perineural dexamethasone administered along with local anesthetic for single sciatic nerve block prolonged the duration of analgesia of quadruple nerve blocks for ACL reconstruction, however the effects were not different from those of intravenous dexamethasone. Amikacin maintained stability within TE, TC, NA and ND over 56 days except when formulated at 10 mg/mL within TE.
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical, P2 data, Clinical Trial,Phase II, Journal: Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. (Pubmed Central) - Jan 11, 2022 P2 The durable 3-year response, overall survival, and progression-free survival rates for asymptomatic patients support first-line use of nivolumab plus ipilimumab. Symptomatic disease in patients with MBM remains difficult to treat, but some patients achieve a long-term response with the combination.
- |||||||||| Ninlaro (ixazomib) / Takeda
Clinical, Retrospective data, Journal: Efficacy of total oral regimens containing ixazomib in patients with relapsed and refractory multiple myeloma (Pubmed Central) - Jan 11, 2022 The ORR was 41.7% in patients receiving ixazomib-lenalidomide-dexamethasone (IRD) regimen...The ORR was 29.0% in bortezomib-refractory patients, 38.0% in lenalidomide-refractory patients, 21.4% in bortezmoib & lenalidomide dual refractory patients...In the treatment of relapsed/refractory multiple myeloma patients with multidrug resistance, the total oral regimens containing ixazomib demonstrate reliable efficacy and safety. Early administration of ixazomib at first or second relapse is suggested for more favorable clinical outcome.
- |||||||||| dexamethasone / Generic mfg.
Enrollment change, Trial withdrawal: Study of Value of Dexamethasone Used in Ovulation Induction (clinicaltrials.gov) - Jan 11, 2022 P=N/A, N=0, Withdrawn, If effective, this therapy might improve outcome and become a therapeutic adjunct for patients with CS. N=460 --> 0 | Suspended --> Withdrawn
- |||||||||| hydrocortisone / Generic mfg.
Trial completion date, Trial primary completion date: CORVICTES: Vitamin C, Hydrocortisone and Thiamine for Septic Shock (clinicaltrials.gov) - Jan 11, 2022 P2, N=400, Recruiting, Recruiting --> Completed Trial completion date: Sep 2021 --> Oct 2022 | Trial primary completion date: Jul 2021 --> Jul 2022
|